logo

FDA Calendar

Share
Company Name Blueprint Medicines
Drug Name Pralsetinib (NDA)
Event Name FDA decision on Pralsetinib for the treatment of locally advanced or metastatic RET fusion-positive NSCLC
Event Date 11/23/2020
Outcome Date
Outcome
Drug Status Priority review
Rival Drugs
Market Potential
Other Approvals
News
Return to FDA Calendar